Tuesday, Oct 7, 2003
South San Francisco, Calif. -- October 7, 2003 --Genentech, Inc. (NYSE: DNA) today announced two senior appointments in the company's Commercial Operations and Research organizations: Diane Parks' promotion to senior vice president and general manager, Specialty Biotherapeutics and Managed Care, and Vishva Dixit's promotion to vice president, Research - Molecular Oncology.
Senior Vice President and General Manager
Specialty Biotherapeutics and Managed Care
Diane Parks, 50, joined Genentech in 1999 as vice president of Marketing and later served as vice president, Managed Care and Commercial Operations. In January 2002, she was named vice president, Specialty Biotherapeutics and Commercial Operations, leading one of the two commercial business units for Genentech. In her position as senior vice president and general manager, Specialty Biotherapeutics and Managed Care, Parks will continue to lead three business franchises - Immunology, Vascular Medicine, and Specialty Therapeutics - while also continuing to lead Genentech's Managed Care organization, which is responsible for business relationships with the nation's healthcare providers.
"Diane has played an integral role in advancing the Specialty Biotherapeutics business unit," said Myrtle Potter, executive vice president, Commercial Operations, and chief operating officer. "This promotion recognizes Diane's significant contributions to the Commercial organization, as well as Genentech's commitment to developing a diverse portfolio of products focused on improving patient lives."
Prior to joining Genentech, Parks held several positions at Marion Laboratories, now known as Aventis, Inc. In 1998, she was named vice president, Marketing. Prior to holding that position, she was group product director of the Respiratory and Metabolism group, director of U.S. Commercial Development, director of Business Information, manager of Marketing Research and senior marketing research analyst. Before working at Marion Laboratories, Parks was a marketing research account manager with Barkley & Evergreen.
Parks holds a bachelor's degree from Kansas State University and a master's of business administration in marketing from Georgia State University.
Research - Molecular Oncology
Vishva Dixit, 47, joined Genentech in 1997 as the director of the Molecular Oncology department and was promoted to senior director in 2000. While at Genentech, Dixit has been responsible for overseeing the research programs focused on understanding the biology of cancer and discovering novel oncology therapeutics. In his position as vice president, Research - Molecular Oncology, Dixit will continue to supervise Genentech's Molecular Oncology research program and move projects into the drug development pipeline. Dixit's laboratory is currently working on characterizing the components of the apoptotic, or cell death pathway, as well as members of the tumor necrosis factor family of ligands and receptors.
"Drawing upon his strong expertise in the field of oncology, Vishva has led the advancement of the research and clinical development of Genentech's Molecular Oncology department," said Richard Scheller, executive vice president, Research. "I am confident that he will continue to help build Genentech's world-class oncology franchise."
Dixit received his medical degree from the University of Nairobi in Nairobi, Kenya. He completed his internship at Kenyatta National Hospital before finishing his residency in medicine at the Barnes Hospital at the Washington University School of Medicine and becoming a postdoctoral fellow at Washington University.
Prior to joining Genentech, Dixit was a professor in the Department of Pathology at the University of Michigan Medical School. Dixit continues to teach as an adjunct professor in the Department of Pharmaceutical Chemistry at the University of California, San Francisco and has authored or co-authored more than 100 scientific articles.
Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. Sixteen of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes 11 biotechnology products in the United States. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit http://www.gene.com.